The European Commission has granted marketing authorisation for Leqembi (lecanemab), making it the first therapy in the EU to slow the progression of early Alzheimer’s disease.

Real-world data from the University of Catania, Italy, suggest that Pepaxti, a treatment for relapsed, refractory multiple myeloma (RRMM), is effective and well tolerated in heavily pretreated ...